ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

Affiliations

¹ Department I for Internal Medicine, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University of Cologne, Cologne, Germany.
² Medical School, Università Vita-Salute San Raffaele, Milan; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
³ Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
⁴ Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁵ Division of Hematology, Luzerner Kantonsspital, Luzern, Switzerland.
⁶ Department I for Internal Medicine, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University of Cologne, Cologne, Germany; Cluster of Excellence-Cologne Excellence on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
⁷ Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden.
⁸ Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm (CCCU), University Hospital of Ulm, Ulm, Germany.

Free article

Practice Guideline

B Eichhorst et al. Ann Oncol. 2024 Sep.

Free article

. 2024 Sep;35(9):762-768.

doi: 10.1016/j.annonc.2024.06.016. Epub 2024 Jul 3.

¹ Department I for Internal Medicine, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University of Cologne, Cologne, Germany.
² Medical School, Università Vita-Salute San Raffaele, Milan; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
³ Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
⁴ Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁵ Division of Hematology, Luzerner Kantonsspital, Luzern, Switzerland.
⁶ Department I for Internal Medicine, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University of Cologne, Cologne, Germany; Cluster of Excellence-Cologne Excellence on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
⁷ Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden.
⁸ Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm (CCCU), University Hospital of Ulm, Ulm, Germany.

No abstract available

Keywords: BCL2 inhibitor; BTK inhibitor; chronic lymphocytic leukaemia; guideline update; ibrutinib–venetoclax; time-limited targeted therapy.

Publication types